XtalPi secures $15m to boost AI drug development and design offering

By Flora Southey

- Last updated on GMT

(Image: Getty/monsitj)
(Image: Getty/monsitj)

Related tags Pharmacology

XtalPi is advancing artificial intelligence models and prediction-driven research capabilities to improve drug design and small molecule development services.

The digital drug discovery and development firm announced it had closed a Series B funding round of $15m (€12m) on Tuesday, with investors including Sequoia China, Google, and Tencent.

According to XtalPi – which helps companies identify promising candidates and improve drug design in preclinical stages – the investment will help develop computational models to boost its proprietary Intelligent Digital Drug Discovery and Development (ID4) offering.

The ID4 platform is driven by artificial intelligence (AI), quantum physics, and cloud computing.

Spokesperson Ruyu Wang told us the investment will also contribute to the construction of a “prediction-driven research lab that can conduct targeted smaller-scale experiments to test and verify its predictions that will be faster than current experiments.”

“This will further expedite the R&D process and increase researchers’ abilities to screen and rationally design the solid forms of drugs,” ​she added.

According to Wang, the project will benefit firms developing small molecule drugs looking to increase R&D rates, drug design, and the preclinical development process.

The company expects to see more growth in the firm’s technologies to help advance pharmaceutical innovation, while reducing time and cost, she told us.

Earlier this month​, Sequoia China joined Google Ventures, Neptune Ventures and Oxford Sciences Innovation in funding Vaccitech – a vector-based vaccine tech firm developing a universal influenza vaccine.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more